4D Molecular Therapeutics To Present Interim Phase 1/2 AEROW Clinical Trial Data At 47th European Cystic Fibrosis Conference; says Showed Clinically Meaningful Improvements In ppFEV1 At 12 Months In 2 Of 3 Participants
Portfolio Pulse from Benzinga Newsdesk
4D Molecular Therapeutics (FDMT) will present interim Phase 1/2 AEROW clinical trial data at the 47th European Cystic Fibrosis Conference. The data showed clinically meaningful improvements in ppFEV1 at 12 months in 2 of 3 participants.
June 06, 2024 | 11:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
4D Molecular Therapeutics (FDMT) will present interim Phase 1/2 AEROW clinical trial data showing clinically meaningful improvements in ppFEV1 at 12 months in 2 of 3 participants.
The positive interim data from the AEROW clinical trial indicates potential efficacy of FDMT's treatment, which is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100